<DOC>
	<DOC>NCT00787878</DOC>
	<brief_summary>The study is conducted in Europe. The primary aim of this observational study is to compare the insulin sensitivity in small for gestational age (SGA) subjects treated with Norditropin速 with untreated small for gestational age (SGA) subjects and with average for gestational age (AGA) subjects.</brief_summary>
	<brief_title>Long Term Metabolic Safety of Norditropin速 Treatment of Small for Gestational Age (SGA) Subjects</brief_title>
	<detailed_description />
	<criteria>Norditropin速 treated small for gestational age (SGA) group: Treated with Norditropin速 for at least three years in the IUGR1 or IUGR2 trials Untreated small for gestational age (SGA) group: Birth length and/or weight less than 2 SDS for gestational age Average gestational age (AGA) group: Birth length and/or weight larger than 2 SDS for gestational age Growth hormone deficiency defined as a peak growth hormone (GH) less than 20 mU/l Insulin like growth (IGF)1 level less than 2 SDS Receipt of any investigational drug within four weeks prior to the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>